ArticleFrontiers in pediatrics2025
Compound sulfamethoxazole for pediatric pertussis: a retrospective cohort study in a region with high macrolide resistance.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, the incidence of pertussis has been increasing globally. The high prevalence of macrolide-resistant strains has led to a significant rise in both pertussis cases and associated mortality. Objective: This retrospective study aimed to evaluate the clinical effectiveness and safety of compound sulfamethoxazole (SMZco) vs. macrolides in pediatric pertussis treatment under real-world clinical conditions, providing evidence for its clinical application. Methods: Patients were divided into macrolide and SMZco groups based on treatment regimens. Comparative analyses included overall treatment effectiveness, duration of nocturnal coughing, paroxysmal coughing, post-tussive vomiting, hospitalization length, and adverse drug reactions. Results: The macrolide group ( Conclusion: SMZco significantly improves treatment effectiveness, shortens symptom duration and hospitalization, and reduces economic burden in pediatric pertussis. These findings position SMZco as an effective and safe alternative, particularly in regions with high macrolide resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.